Glynamic MV 1 Tablet is a combination oral hypoglycemic agent containing Glimepiride (1mg), Metformin (500mg), and Voglibose (0.2mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby enhancing endogenous insulin levels. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, contributing to decreased blood glucose levels without causing significant hypoglycemia. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, effectively reducing postprandial hyperglycemia. The synergistic action of these three agents addresses multiple pathophysiological defects in type 2 diabetes, promoting better overall glycemic management. Glynamic MV 1 is indicated for patients inadequately controlled on diet, exercise, and monotherapy with either sulfonylurea or metformin alone. It should be administered under medical supervision with appropriate monitoring of blood glucose levels and renal function. Caution is advised in patients with hepatic or renal impairment, and gastrointestinal side effects such as flatulence or diarrhea may occur due to voglibose. This combination therapy offers a comprehensive approach to diabetes management, improving patient compliance by reducing pill burden while optimizing glycemic control.